Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy

J Neurosci. 2001 Aug 1;21(15):5678-84. doi: 10.1523/JNEUROSCI.21-15-05678.2001.

Abstract

Physical exercise ameliorates age-related neuronal loss and is currently recommended as a therapeutical aid in several neurodegenerative diseases. However, evidence is still lacking to firmly establish whether exercise constitutes a practical neuroprotective strategy. We now show that exercise provides a remarkable protection against brain insults of different etiology and anatomy. Laboratory rodents were submitted to treadmill running (1 km/d) either before or after neurotoxin insult of the hippocampus (domoic acid) or the brainstem (3-acetylpyridine) or along progression of inherited neurodegeneration affecting the cerebellum (Purkinje cell degeneration). In all cases, animals show recovery of behavioral performance compared with sedentary ones, i.e., intact spatial memory in hippocampal-injured mice, and normal or near to normal motor coordination in brainstem- and cerebellum-damaged animals. Furthermore, exercise blocked neuronal impairment or loss in all types of injuries. Because circulating insulin-like growth factor I (IGF-I), a potent neurotrophic hormone, mediates many of the effects of exercise on the brain, we determined whether neuroprotection by exercise is mediated by IGF-I. Indeed, subcutaneous administration of a blocking anti-IGF-I antibody to exercising animals to inhibit exercise-induced brain uptake of IGF-I abrogates the protective effects of exercise in all types of lesions; antibody-treated animals showed sedentary-like brain damage. These results indicate that exercise prevents and protects from brain damage through increased uptake of circulating IGF-I by the brain. The practice of physical exercise is thus strongly recommended as a preventive measure against neuronal demise. These findings also support the use of IGF-I as a therapeutical aid in brain diseases coursing with either acute or progressive neuronal death.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Behavior, Animal
  • Cell Count
  • Cerebellar Diseases / blood
  • Cerebellar Diseases / pathology
  • Cerebellar Diseases / therapy
  • Disease Models, Animal
  • Disease Progression
  • Glucose / metabolism
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Hippocampus / pathology
  • Immunohistochemistry
  • Injections, Subcutaneous
  • Insulin-Like Growth Factor I / administration & dosage
  • Insulin-Like Growth Factor I / metabolism*
  • Kainic Acid / analogs & derivatives*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Motor Activity
  • Neurodegenerative Diseases / etiology
  • Neurodegenerative Diseases / pathology
  • Neurodegenerative Diseases / physiopathology*
  • Neurodegenerative Diseases / therapy
  • Neurons / pathology
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / metabolism
  • Olivary Nucleus / drug effects
  • Olivary Nucleus / pathology
  • Physical Conditioning, Animal*
  • Purkinje Cells / pathology
  • Pyridines
  • Rats
  • Rats, Wistar
  • Treatment Outcome

Substances

  • Neuroprotective Agents
  • Pyridines
  • 3-acetylpyridine
  • Insulin-Like Growth Factor I
  • Glucose
  • domoic acid
  • Kainic Acid